Exclusive-US weighs allowing most pharma licensing deals with China, sources say
The US is weighing permission for most pharmaceutical licensing deals with China, according to sources cited by Investing.com. The proposal could ease a channel for cross-border drug partnerships, but its scope and timing remain unsettled.
STOCK PHOTO · PHIL EVENDENThe story
The policy under consideration would allow most pharmaceutical licensing agreements involving China, according to sources cited by Investing.com. No final decision, implementation timetable or list of transactions covered was specified.
The proposal would represent a potentially less restrictive approach to pharma-related commercial ties between the US and China. Its practical effect would depend on the kinds of licenses covered and on any remaining controls affecting technology, data, investment or end-use.
US and Chinese pharmaceutical companies could be affected through licensing fees, development partnerships and rights to commercialize medicines in the other market. The mechanism is contractual: a broader permitted set of deals could expand the number of cross-border transactions that can proceed, while narrower rules would limit the benefit.
The report attributes the proposal to sources, and the policy has not been presented as a completed decision. The details of any exemptions, review process and enforcement conditions are therefore open.
The next concrete markers are a formal US policy announcement and any accompanying guidance defining which licensing agreements qualify. Company-specific read-through would require named deals or transaction disclosures after those rules are clarified.
Our read · Fri, Sep 18
The US is weighing permission for most pharmaceutical licensing deals with China, sources say.
Why. The immediate implication is a possible easing of a major transaction constraint, which could improve the path for US-China pharma licensing agreements. Because the proposal is attributed to sources and its scope is undefined, the commercial impact cannot yet be assigned to a specific company or revenue line.
Both cases
What could change this view: A narrower policy, added review conditions or no formal change would remove the expected benefit to cross-border licensing activity.
Who reported it · 1
Keep reading
Latest on the Wire
AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →Latest on the Wire
PIF Tower in Riyadh reportedly damaged in second Houthi attackTrump Media buys back $100 million of notes ahead of Nov. 30 cash demandBiohaven reports confirmed BHV-1530 responses in two FGFR3 cancersTrump, Xi and Putin pledge more refined fuel after first trilateral summitContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by Investing.com, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →